July 10, 2015
JPMA Regulatory Affairs Committee Chairman Masaaki Kuwahara A Japanese version of compassionate use is expected to place a huge burden on drug makers as they will be urged to conduct additional unscheduled trials for a humanitarian cause, said the regulatory...read more